Shilpa Medicare Q4 FY26 Results: PAT Rs 89 Cr
- May 22, 2026
- Posted by: Kashish Aggarwal
- Category: News
Shilpa Medicare Q4 FY26 results were declared on May 22, 2026. The company reported PAT of Rs 89 crore for the quarter ended March 31, 2026, up 641.0% YoY compared to Rs 12 crore in Q4 FY25. Revenue from operations was Rs 437 crore, up 32.0% YoY. Results are on a Consolidated basis. Shilpa Medicare is a Pharmaceuticals and APIs company listed on Indian stock exchanges.
Click Here – Get Free Investment Predictions
Shilpa Medicare Q4 FY26 Financial Highlights
| Metric | Q4 FY26 (Rs Cr) | Q4 FY25 (Rs Cr) | YoY Change |
|---|---|---|---|
| Revenue | Rs 437 crore | Rs 331 crore | +32.0% |
| Gross Profit | Rs 89 crore | Rs 48 crore | +85.0% |
| Net Profit | 89 | 12 | +641.0% |
| Basis | Consolidated | ||
Note: Shilpa Medicare Q4 FY26 results declared May 22, 2026. Verify from BSE/NSE audited filings before investment decisions.
Shilpa Medicare Q4 FY26 Performance Analysis
The Shilpa Medicare Q4 FY26 results reflect the company’s operational performance during the January to March 2026 quarter. The strong PAT growth of 641% YoY demonstrates significant earnings improvement and operational leverage. Shilpa Medicare operates in the Pharmaceuticals and APIs sector, which is supported by India’s GDP growth above 6.5% and domestic demand tailwinds in FY26.
Revenue of Rs 437 crore was up 32.0% YoY. Strong revenue growth reflects market share gains and healthy demand.
Screen the best stocks on the Univest Screener.
Key Factors Driving Shilpa Medicare Q4 FY26 Results
Revenue Performance
Revenue of Rs 437 crore in Shilpa Medicare Q4 FY26 was up 32.0% YoY. The double-digit topline growth reflects strong end-market demand, market share gains, and favourable pricing conditions in the Pharmaceuticals and APIs sector. The January to March 2026 quarter is the year-end quarter, characterised by strong order execution and fiscal year-end activity across Indian corporates.
Profitability and Margin Analysis
The Shilpa Medicare Q4 FY26 PAT of Rs 89 crore up 641.0% YoY. The exceptional PAT growth of 641% YoY reflects strong operating leverage, margin expansion, and improved cost efficiency.
Sector Tailwinds and India Macro Environment
The Pharmaceuticals and APIs sector saw constructive operating conditions in Q4 FY26. India’s macroeconomic environment, with GDP growth above 6.5%, government capital expenditure of Rs 11.21 lakh crore budgeted for FY27, and resilient domestic consumption, supported demand across sectors. The Reserve Bank of India’s accommodative liquidity stance aided credit conditions. For Shilpa Medicare, these macro and sectoral tailwinds provided a supportive backdrop in the January to March 2026 quarter.
FY27 Outlook
Following Shilpa Medicare Q4 FY26 results, management commentary on FY27 revenue guidance, margin trajectory, capex plans, and demand pipeline will be the key investor focus areas. The Pharmaceuticals and APIs sector benefits from India’s long-term growth story including urbanisation, infrastructure investment, and rising middle-class consumption. Sustaining the strong earnings momentum and margin profile will be the FY27 priority.
Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.
Frequently Asked Questions on the company
What is Shilpa Medicare Q4 FY26 net profit?
Ans. Shilpa Medicare Q4 FY26 PAT of Rs 89 crore, up 641.0% YoY from Rs 12 crore in Q4 FY25. Results declared May 22, 2026, on a Consolidated basis. Verify from BSE/NSE audited filings.
What is Shilpa Medicare Q4 FY26 revenue?
Ans. Shilpa Medicare Q4 FY26 revenue from operations was Rs 437 crore, up 32.0% YoY. Verify complete financials from BSE/NSE filings.
When were Shilpa Medicare Q4 FY26 results declared?
Ans. Shilpa Medicare Q4 FY26 results were declared on May 22, 2026, at the board of directors meeting approving audited Q4 and full-year FY26 financial statements.
Is Shilpa Medicare a good investment after Q4 FY26 results?
Ans. Investment decisions require individual assessment of fundamentals, valuation, and risk tolerance. This article is for educational purposes only and does not constitute investment advice. Consult a SEBI-registered financial advisor before investing in Shilpa Medicare.
Also Read
- Sun Pharma Q4 FY26 Results: PAT Rs 2,724 Crore
- Minda Corporation Q4 FY26 Results: PAT Rs 93 Crore
- Star Cement Q4 FY26 Results: PAT Rs 147 Crore
- Univest Blogs: Latest Stock Market Research and Analysis
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Verify all figures from BSE/NSE filings. Consult a SEBI-registered financial advisor.
